clinical trial · NCT07500207
A Phase III Clinical Trial on Immunogenicity and Safety of Lyophilized Rabies Vaccine for Human Use (Human Diploid Cell)
Changchun BCHT Biotechnology Co.·phase3·enrolling by invitation·n = 3,000
Rabies PreventionExperimental Lyophilized Human Rabies Vaccine (Human Diploid Cell)approved Rabies vaccine
brief summary
Neutralizing antibody seroconversion rate and geometric mean concentration in seronegative participants of each group at 14 days after the first dose of immunization. The seroconversion rate of neutralizing antibodies 42 days after the first dose among seronegative participants before vaccination in each group
started
Mar 4, 2026
primary completion
May 25, 2026
completion
Mar 25, 2027
last updated
Mar 30, 2026
official title
A Phase III Clinical Trial to Evaluate the Immunogenicity and Safety of Lyophilized Human Rabies Vaccine (Human Diploid Cell) Administered Via Different Immunization Schedules Using a Randomized, Blinded, Positive-Controlled Design
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol